Opioid Peptides Rise During Blood Pressure Spikes in Hypertensive Patients

During acute blood pressure increases in hypertensive patients, beta-endorphin, met-enkephalin, and dynorphin B levels all changed significantly, alongside natriuretic peptide and endothelin-1 alterations.

Fontana, F et al.·Hypertension (Dallas·1997·Moderate Evidenceclinical-trial
RPEP-00408Clinical TrialModerate Evidence1997RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Beta-endorphin, met-enkephalin, and dynorphin B levels changed significantly during acute blood pressure increases in hypertensive patients, alongside ANF and endothelin-1 alterations.

Key Numbers

How They Did This

Clinical trial measuring plasma levels of three opioid peptides, catecholamines, ANF, and endothelin-1 in hypertensive patients before and after naloxone administration during acute BP episodes.

Why This Research Matters

Understanding the opioid system's role in hypertensive crises could lead to new treatment strategies using opioid pathway modulation for blood pressure management.

The Bigger Picture

This study placed opioid peptides alongside established cardiovascular mediators (ANF, endothelin) in the complex regulatory network of blood pressure control.

What This Study Doesn't Tell Us

Clinical trial in selected hypertensive patients during acute episodes. Small study with limited generalizability. Naloxone has its own cardiovascular effects.

Questions This Raises

  • ?Could opioid pathway modulation help manage hypertensive crises?
  • ?Are baseline opioid peptide levels predictive of hypertension severity?

Trust & Context

Key Stat:
3 opioid peptides altered in BP spikes Beta-endorphin, met-enkephalin, and dynorphin B all showed significant changes during acute hypertensive episodes
Evidence Grade:
Moderate clinical evidence from a naloxone-challenge study in hypertensive patients.
Study Age:
Published in 1997, contributing to understanding of opioid involvement in cardiovascular regulation.
Original Title:
Pressor effects of endogenous opioid system during acute episodes of blood pressure increases in hypertensive patients.
Published In:
Hypertension (Dallas, Tex. : 1979), 29(1 Pt 1), 105-10 (1997)
Database ID:
RPEP-00408

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why do opioid peptides change during blood pressure spikes?

The body releases opioid peptides as part of its stress response during acute BP increases. These peptides may serve as natural vasodilators trying to bring blood pressure back down, or they may reflect the intensity of the cardiovascular stress.

What does the naloxone test reveal?

Naloxone blocks opioid receptors. By measuring blood pressure before and after naloxone, researchers can determine how much of the blood pressure response is mediated by opioid peptides.

Read More on RethinkPeptides

Cite This Study

RPEP-00408·https://rethinkpeptides.com/research/RPEP-00408

APA

Fontana, F; Bernardi, P; Spampinato, S; Boschi, S; De Iasio, R; Grossi, G. (1997). Pressor effects of endogenous opioid system during acute episodes of blood pressure increases in hypertensive patients.. Hypertension (Dallas, Tex. : 1979), 29(1 Pt 1), 105-10.

MLA

Fontana, F, et al. "Pressor effects of endogenous opioid system during acute episodes of blood pressure increases in hypertensive patients.." Hypertension (Dallas, 1997.

RethinkPeptides

RethinkPeptides Research Database. "Pressor effects of endogenous opioid system during acute epi..." RPEP-00408. Retrieved from https://rethinkpeptides.com/research/fontana-1997-pressor-effects-of-endogenous

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.